Prostate Cancer Radionuclide Therapy
Radionuclide therapy involves the attempt to kill cancer cells and the surrounding affected tissue with radioactive materials. The advantages of radionuclide therapy include the fact that, depending on the form of treatment, it is either noninvasive or much less invasive than surgery. Bone-seeking radiopharmaceuticals or radionuclides are used to treat prostate cancer if it has spread to the bones. The drug is injected intravenously and is absorbed into the bones. It is a single outpatient treatment that can be administered in the doctor’s office.
Bone metastases are the most common cause of pain in advanced prostate cancer patients resulting from tumor infiltration and extension of the periosteal membranes, mechanical instability, tumor-induced cytokines, stimulating factors, and tumor spread from the bone to contiguous neurological structures. The management of bone pain continues to be a major therapeutic challenge and involves a multidisciplinary...
KeywordsRadionuclide Therapy Beta Particle Penetration Range Shared Toilet Bone Pain Palliation
- Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germa JR, O’Bryan-Tear CG et al (2013) A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63:189–197CrossRefPubMedGoogle Scholar
- (2012) Cytopenia. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1056. doi: 10.1007/978-3-642-16483-5_1484Google Scholar